DOI:
10.1055/s-00000004
Aktuelle Neurologie
LinksClose Window
References
Thebault JJ, Guillaume M.
Phase I clinical trials of TVP-1012 (rasagiline mesylate), a selective inhibitor of monoamine oxidase B, for treatment of Parkinson's disease.
Mov Disord 1997; 12, Suppl 1: 106-
Search in:
We do not assume any responsibility for the contents of the web pages of other providers.